Wednesday’s biggest gaining and declining stocks

Atlanta, GA 6/20/12 (StreetBeat) -- Here are some of Wednesday’s biggest gaining and declining stocks in U.S. trading:

Gainers

Identix Pharmaceuticals Inc. (Nasdaq:IDIX) shares jumped 12%. The company reported positive data from ongoing clinical trials for its hepatitis C treatment.

Gevo Inc. (Nasdaq:GEVO) shares rallied 37% after the company said a court had ruled in its favor in a case where rival Butamax Advanced Biofuels LLC had sought an injunction against the company’s sale of certain products.

WSI Industries Inc. (Nasdaq:WSCI) shares added 22%. A day earlier, the company posted a 51% jump in fiscal third-quarter profit on a 45% sales improvement.

Decliners

Adobe Systems Inc. (Nasdaq:ADBE) fell 5.1%. After the market closed on Tuesday, the firm said its fiscal second-quarter earnings dropped 2.4%.

AspenBio Pharma Inc. (Nasdaq:APPY) shares tumbled 36% after the firm said it will sell 6.1 million shares at $2 per share. That’s a 36% discount to the shares’ closing price on Tuesday.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

Inhibitex (Nasdaq: INHX) Shares Soar as Investors See Another Pharmasset in the Making

Tallahassee, FL 11/4/11 (StreetBeat) -- Shares of Inhibitex (Nasdaq: INHX) more than doubled Friday morning after the company released promising new data on its hepatitis C drug candidate.

The Inhibitex drug INX-189 belongs to the same "nucleoside" class of potent oral hepatitis C drugs as Pharmasset's (Nasdaq: VRUS) heralded PSI-7977. The difference, of course, is that Inhibitex's market value is $300 million, or at least it was going into Friday's trading. Pharmasset's market value is close to $6 billion.

Investors are hoping that the magical Hep C pixie dust that has made Pharmasset the best-performing biotech stock this year will work its charms on Inhibitex as well.

Inhibitex shares soared 133% to $9.25 in pre-market trading after the company reported a 4.25 log drop in Hep C viral load after 7 days of treatment with a 200mg dose of INX-189 in treatment-naive patients. No serious adverse events were reported. That result is comparable to the viral load decline demonstrated by Pharmasset's PSI-7977 in an earlier study.

Nucleoside or "nucs" have become the belles of the Hep C drug ball because of their potential as a backbone of future all-oral combination Hep C therapy. Pharmasset's nuc PSI-7977 has garnered the most attention, but companies like Inhibitex and Idenix Pharmaceuticals (Nasdaq: IDIX) are also developing their own Hep C nucs.

Pharmasset shares were down 4% to $74.80 in early Friday trading, likely due to competitive concerns stemming from the INX-189 data. In Friday's release, Inhibitex said it was moving forward with new studies of INX-189 including one in combination with an another undisclosed direct-acting antiviral Hep C drug.

The new Inhibitex data on INX-189 comes on the eve of the American Association for the Study of Liver Disease (AASLD) annual meeting, which will feature important presentations of new hepatitis C drug research.

StreetBeat Disclaimer

Distributed by Viestly